Peptide therapy results timeline: for approved weight-loss peptides, results build over months, not days. On semaglutide 2.4 mg, people lost about 10.6% of their body weight by week 20[1] and 14.9% by week 68.[2] On tirzepatide 15 mg, average loss reached 20.9% at week 72.[3] For most unapproved peptides, such as BPC-157, the honest timeline is “unknown,” because no controlled human trials have measured one.[12]
This guide sets out what trials show, when to reassess, and how to plan checkpoints with your clinician. Your own results may be faster, slower or absent; a clinician should guide decisions. For basics, see the peptide basics hub.
Why timelines differ
- Dose escalation: GLP-1 drugs start low and step up over 16 weeks or more to limit nausea, so full effects come later. Our semaglutide dosage chart and tirzepatide dosage chart show the steps.
- What’s being measured: appetite can change within weeks; weight, body fat and blood sugar markers take months.
- The marker itself: A1C reflects average blood sugar over the past 2 to 3 months, so it can’t show a full effect any sooner.[9]
Timeline for approved peptides
| Peptide and goal | Early sign | Main trial result | When to reassess |
|---|---|---|---|
| Semaglutide 2.4 mg, weight | ~10.6% loss by week 20[1] | 14.9% at week 68[2] | With your clinician, after reaching the maintenance dose |
| Tirzepatide, weight | 82% lost 5%+ by week 12[4] | 20.9% at week 72 (15 mg)[3] | Week 24 or later; most slow starters still respond[4] |
| Liraglutide 3 mg (Saxenda), weight | — | — | Stop if under 4% loss by week 16[5] |
| Semaglutide, type 2 diabetes | Blood sugar falls in weeks | A1C down 1.45 to 1.55 points at week 30[8] | After about 3 months, when A1C can reflect the change |
| Tesamorelin, HIV-related belly fat | — | Visceral fat down 15.2% at week 26[6] | Consider stopping if visceral fat hasn’t fallen[7] |
For more detail, see how long semaglutide takes to work and how long tirzepatide takes to work.
Blood sugar and body fat follow their own clocks
Type 2 diabetes. In SUSTAIN 1, people starting with an average A1C of 8.05% saw it fall by 1.45 points on semaglutide 0.5 mg and 1.55 points on 1 mg after 30 weeks, compared with almost no change on placebo.[8] Because A1C reflects the previous 2 to 3 months,[9] a test after only a few weeks understates the effect. Home glucose readings can show changes sooner.
Visceral fat. Tesamorelin works through the growth hormone system rather than appetite. In its main trial of 412 adults with HIV and abdominal fat buildup, daily injections for 26 weeks cut visceral fat by 15.2%, lowered triglycerides by 50 mg/dL and raised IGF-1 by 81%; on placebo, visceral fat rose 5.0%.[6] The label asks prescribers to weigh continuing treatment in people whose visceral fat hasn’t fallen.[7] Those results apply to that specific condition, not to general fat loss.
Slow starters aren’t always non-responders
In SURMOUNT-1, 18% of consistent tirzepatide users had lost less than 5% of their weight by week 12. Of those, 70% reached 5% by week 24 and 90% by week 72, taking about 25 weeks on average.[4] This analysis was funded by the manufacturer and looked back at existing data, but it suggests an early slow start isn’t a reason to give up by itself. Our guide to not losing weight on a GLP-1 covers common reasons for a slow response.
Other drugs have firmer stopping rules. For Saxenda (liraglutide), the manufacturer tells prescribers to stop treatment in adults who haven’t lost at least 4% of body weight by week 16.[5]
Unapproved peptides: an honest “unknown”
For peptides like BPC-157, TB-500, ipamorelin or epitalon, there are no controlled human trials that tracked results over time for the goals they’re sold for. A 2025 systematic review of BPC-157 found 35 preclinical studies and a single retrospective clinical study, in which 7 of 12 people with knee pain reported relief lasting more than six months.[12] That’s not enough to say how long it takes to work, or whether it does.
Results don’t always last after stopping
For GLP-1 weight-loss drugs, the effect depends on staying on treatment:
- Semaglutide: one year after stopping in STEP 1, people had regained about two-thirds of the weight they’d lost, and most heart-health markers drifted back toward baseline.[10]
- Semaglutide, switched to placebo: in STEP 4, people who switched after 20 weeks regained 6.9% of body weight by week 68, while those who continued lost another 7.9%.[1]
- Tirzepatide: in SURMOUNT-4, people switched to placebo after 36 weeks regained 14.0% of body weight by week 88, while those who stayed on it lost another 5.5%.[11]
See stopping a GLP-1 for how to plan for this.
How to plan your own checkpoints
- Agree on one measurable goal with your clinician before starting.
- Record a baseline: weight, waist, relevant lab tests or symptoms. Our peptide clinic lab tests guide explains which tests matter.
- Set a first checkpoint that matches the trial evidence, such as week 12 to 16 for weight-loss drugs.
- Decide in advance what result would mean continuing, adjusting the dose or stopping.
- Track side effects alongside results; benefits have to outweigh them.
Checklist: setting realistic expectations
- I know what the trials found, and over what time.
- My goal and baseline are written down.
- A first checkpoint date is in my calendar.
- I know the stopping rule, if my drug has one.
- I understand what may happen if I stop.
- For an unapproved peptide, I accept the timeline and effect are unknown.
The bottom line
Approved peptides come with timelines measured in trials: weeks for early signs, months to a year or more for full effect. Most other peptides come with promises instead of data. Plan checkpoints with your clinician, judge results against the trial evidence, and treat any timeline without a trial behind it as a guess. Our beginner’s guide to peptides explains how to tell the difference.
